Development asset linked to Tang-Du Hospital in public FDA and regional records.
pharma · Myasthenia Gravis, Generalized
Tang-Du Hospital
Tang-Du Hospital drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Tang-Du Hospital pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tang-Du Hospital drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
tocilizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor